Johnson & Johnson (JNJ) received a high 88% rating from Validea's P/B Growth Investor model, based on Partha Mohanram's academic-backed strategy. This model, designed to identify low book-to-market stocks with characteristics for sustained future growth, indicates strong interest in JNJ, a large-cap Biotechnology & Drugs firm. While JNJ passed most fundamental criteria, including return on assets and cash flow, it notably failed the research and development to assets test, yet still signals significant growth potential according to this methodology.
Johnson & Johnson (JNJ) has received a highly favorable rating of 88% from Validea's P/B Growth Investor model, a quantitative strategy developed by academic Partha Mohanram to identify low book-to-market stocks with potential for sustained growth. This score, which is considered a signal of strong interest, is based on JNJ's performance across several fundamental metrics. The company passed eight key tests, including those for return on assets, cash flow from operations relative to assets, and stability in both sales and ROA variance, indicating robust financial health and operational efficiency. Notably, however, JNJ failed the test for Research and Development to Assets. For a large-cap firm in the Biotechnology & Drugs industry, this is a significant data point. The high overall score suggests that, according to this specific model, JNJ's strong profitability and stable cash generation characteristics currently outweigh the lower relative R&D expenditure, positioning it as a fundamentally sound growth investment.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
